HC Wainwright Comments on AnaptysBio FY2030 Earnings

AnaptysBio, Inc. (NASDAQ:ANAB) – Analysts at HC Wainwright issued their FY2030 earnings per share (EPS) estimates for shares of AnaptysBio in a research note issued to investors on Wednesday, March 4th. HC Wainwright analyst E. Bodnar expects that the biotechnology company will post earnings per share of $7.67 for the year. HC Wainwright has a “Buy” rating and a $66.00 price target on the stock. The consensus estimate for AnaptysBio’s current full-year earnings is ($6.08) per share.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings results on Monday, March 9th. The biotechnology company reported $1.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.89 by $0.69. The company had revenue of $108.25 million for the quarter, compared to analyst estimates of $87.09 million. AnaptysBio had a negative net margin of 5.64% and a negative return on equity of 1,101.24%.

Several other equities research analysts also recently weighed in on ANAB. Wells Fargo & Company upped their price target on AnaptysBio from $51.00 to $81.00 and gave the stock an “overweight” rating in a report on Wednesday, November 5th. Stifel Nicolaus boosted their price target on shares of AnaptysBio from $56.00 to $85.00 and gave the company a “buy” rating in a research report on Thursday. Truist Financial increased their price objective on AnaptysBio from $20.00 to $36.00 and gave the company a “hold” rating in a report on Monday, November 10th. Wedbush restated an “outperform” rating and issued a $50.00 price target on shares of AnaptysBio in a research report on Monday, November 24th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of AnaptysBio in a research report on Wednesday, January 21st. Nine research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $71.89.

AnaptysBio Stock Down 1.0%

AnaptysBio stock traded down $0.58 during mid-day trading on Thursday, reaching $59.97. 193,325 shares of the company’s stock were exchanged, compared to its average volume of 470,587. The company has a market cap of $1.66 billion, a P/E ratio of -115.32 and a beta of 0.32. AnaptysBio has a twelve month low of $15.32 and a twelve month high of $63.47. The company has a fifty day moving average of $50.02 and a 200-day moving average of $38.65.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Federated Hermes Inc. boosted its position in shares of AnaptysBio by 2,236.6% during the 3rd quarter. Federated Hermes Inc. now owns 193,327 shares of the biotechnology company’s stock valued at $5,920,000 after purchasing an additional 185,053 shares in the last quarter. Panagora Asset Management Inc. acquired a new position in AnaptysBio in the second quarter worth approximately $741,000. Assenagon Asset Management S.A. increased its holdings in shares of AnaptysBio by 4,852.7% in the third quarter. Assenagon Asset Management S.A. now owns 839,934 shares of the biotechnology company’s stock valued at $25,719,000 after buying an additional 822,975 shares in the last quarter. Los Angeles Capital Management LLC acquired a new stake in shares of AnaptysBio during the 2nd quarter valued at $334,000. Finally, 683 Capital Management LLC boosted its stake in shares of AnaptysBio by 155.6% during the 2nd quarter. 683 Capital Management LLC now owns 500,000 shares of the biotechnology company’s stock worth $11,100,000 after acquiring an additional 304,373 shares in the last quarter.

Insider Buying and Selling

In other news, CEO Daniel Faga sold 15,309 shares of the business’s stock in a transaction on Monday, January 5th. The stock was sold at an average price of $43.26, for a total value of $662,267.34. Following the completion of the transaction, the chief executive officer directly owned 458,139 shares of the company’s stock, valued at $19,819,093.14. The trade was a 3.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Eric J. Loumeau sold 12,500 shares of the firm’s stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $44.86, for a total transaction of $560,750.00. Following the sale, the insider owned 9,088 shares in the company, valued at approximately $407,687.68. This trade represents a 57.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 156,280 shares of company stock worth $7,254,939. 33.50% of the stock is currently owned by corporate insiders.

AnaptysBio announced that its Board of Directors has initiated a share repurchase program on Friday, November 21st that authorizes the company to buyback $100.00 million in outstanding shares. This buyback authorization authorizes the biotechnology company to repurchase up to 9.6% of its shares through open market purchases. Shares buyback programs are typically a sign that the company’s leadership believes its shares are undervalued.

Key AnaptysBio News

Here are the key news stories impacting AnaptysBio this week:

• Positive Sentiment: Stifel Nicolaus raised its price target sharply to $85 and reiterated a Buy rating, implying meaningful upside versus recent levels — a notable institutional upshift that can attract buyers and support the rally. Stifel Raises PT to $85
• Positive Sentiment: HC Wainwright boosted its target to $66 (Buy) and published a very bullish FY2030 EPS projection (~$7.67), signaling strong analyst conviction about longer?term earnings potential. Analyst upgrades like this add momentum. H.C. Wainwright PT Raise & Estimates
• Positive Sentiment: Barclays nudged its target to $79 with an Overweight rating — another institutional signal supporting demand for the shares. Barclays Raises PT to $79
• Positive Sentiment: Q4 results beat expectations: EPS $1.58 vs. $0.89 est., and revenue $108.3M vs. $87.1M est. The upside to both top and bottom line reduces near?term execution risk and helps justify higher analyst targets. Q4 Earnings Beat
• Positive Sentiment: Management confirmed the planned spin?off of its biopharma portfolio into a new public company, “First Tracks Biotherapeutics,” targeted for Q2 2026. A separation can unlock value by letting each business be valued on its own merits. Spin?off Announcement
• Positive Sentiment: GSK’s Jemperli reported strong commercial performance (Q4 growth), and Anaptys highlighted expected royalty upside — management sees >$390M annualized royalties to Anaptys at peak GSK guidance, which supports longer?term revenue visibility. Jemperli Royalty Outlook
• Neutral Sentiment: Reports show short interest figures as effectively zero/unchanged — likely a data anomaly and not a meaningful driver of price action. Short Interest Data
• Negative Sentiment: Despite the beat, the company still reports a negative net margin and negative return on equity, and consensus models expect losses in the near term (previous consensus for the fiscal year was negative EPS). These fundamentals are a reminder of inherent biotech execution and commercialization risk. Q4 Release & Financials

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.